Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867813 · ClinicalTrials.gov registry record · Phase 3
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
A Phase 3 study of Dyslipidemia, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,035
- Enrollment target
- 20
- Study locations
NCT02867813 is a Phase 3 study of Dyslipidemia that has completed, run by Amgen. The registered enrollment target is 5,035 participants, above the 237-participant average among 40 other Dyslipidemia trials with a reported enrollment target (2024% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02867813, a Phase 3 study of Dyslipidemia, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,035 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
Conditions Studied
Interventions
- BIOLOGICAL Evolocumab
Study Locations (20)
California
- Research Site - Banning
- Research Site - Long Beach
- Research Site - Oceanside
- Research Site - Oxnard
- Research Site - Palm Springs
- Research Site - Roseville
- Research Site - San Diego
- Research Site - San Pedro
- Research Site - Tarzana
- Research Site - Torrance
- Research Site - Valley Village
Colorado
- Research Site - Aurora
- Research Site - Colorado Springs
- Research Site - Denver
- Research Site - Littleton
Alabama
- Research Site - Birmingham
- Research Site - Huntsville
Florida
- Research Site - Boynton Beach
- Research Site - Clearwater
Arizona
- Research Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,035 participants |
| Start Date | 2016-09-02 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02867813
The ClinicalTrials.gov registry entry for NCT02867813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,035 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 237-participant average among 40 other Dyslipidemia trials with a reported enrollment target (2024% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which Evolocumab is the first listed.
NCT02867813 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT02867813 about?
NCT02867813 is a clinical study titled "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension". The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
What is the current status of trial NCT02867813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,035 participants. The study started on 2016-09-02. Estimated completion is 2022-03-21.
What conditions does trial NCT02867813 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT02867813?
The interventions under investigation include: Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02867813?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02867813 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
COMPLETED · Phase 3
-
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
COMPLETED · Phase 3
-
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
COMPLETED · Phase 3
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Cottonseed Oil Versus Matched PUFA Effects
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.